Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron/Organon Teknika

This article was originally published in The Gray Sheet

Executive Summary

Firms ink semi-exclusive, worldwide license for patents relating to the development of assays for detection of HIV in nucleic acid sequences in clinical diagnostics, excluding blood screening. Organon is the third licensee of the patents, including Bayer AG and Roche. Chiron will receive royalty payments based on a percentage of net sales of current and future Organon Teknika offerings, subject to minimum royalties as a fixed amount per test sold

You may also be interested in...



BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit

BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel